Home › Research › Treatments
Antagonic-stress superiority versus meclofenoxate in gerontopsychiatry (alzheimer type dementia)
Popa R, Schneider F, Mihalas G, Stefaniga P, Mihalas IG, Maties R, Mateescu R.. Archives of gerontology and geriatrics, 1994-01-01
Topic: Amyloid, tau and blood-test diagnosis
A double blind, comparative, parallel and randomized clinical trial was used for evaluation of two nootropics with anti-aging actions: Meclofenoxate (MF) and Antagonic-Stress (AS). Sixty-three old persons divided into 2 groups (average age: 68.6 and 70.8 years, respectively) with senile dementia of Alzheimer type (SDAT), of mild to moderate intensity (criteria of DSM-III-R, APA, 1987; and ICD-10, WHO, 1990) were treated with one of these nootropica. Baseline and final psychogeriatric symptomatology after three months of treatments were multiply assessed: psychogeriatric by Sandoz Clinical Assessment-Geriatric scale, Self-Assessment Scale-Geriatric and their subscales; psychometric by Wechsler Memory Scale and Wechsler Adult Intelligence Scale. Prolonged treatments with MF and AS significantly decreased the psychogeriatric scores in scales and subscales, improved the cognitive performance (attention, concentration, memory, performance IQ, full IQ) and diminshed the deterioration index (ANOVA). Therapeutical effects of AS (a neurometabolic complex containing MF) were significantly superior against MF alone (ANCOVA). MF and AS actions are discussed in connection with the brain cholinergic system, lipid peroxidation and free radical scavengers, deceleration of the aging rate, brain and erythrocyte lipofuscinolysis, multiple anti-oxidant formula, multivitamin and multimineral supplementation and with the superiority of multitherapy versus monotherapy in senile dementia and for improving the IQ and the maladaptative behavior.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Popa, R., Schneider, F., Mihalas, G., Stefaniga, P., Mihalas, I. G., Maties, R., et al. (1994). Antagonic-stress superiority versus meclofenoxate in gerontopsychiatry (alzheimer type dementia). Archives of gerontology and geriatrics. https://doi.org/10.1016/s0167-4943(05)80065-2
Vancouver
Popa R, Schneider F, Mihalas G, Stefaniga P, Mihalas IG, Maties R, et al. Antagonic-stress superiority versus meclofenoxate in gerontopsychiatry (alzheimer type dementia). Archives of gerontology and geriatrics. 1994. doi:10.1016/s0167-4943(05)80065-2. PMID: 18649860.
BibTeX
@article{popa1994-18649860,
author = {Popa, R. and Schneider, F. and Mihalas, G. and Stefaniga, P. and Mihalas, I. G. and Maties, R. and Mateescu, R.},
title = {{Antagonic-stress superiority versus meclofenoxate in gerontopsychiatry (alzheimer type dementia)}},
journal = {Archives of gerontology and geriatrics},
year = {1994},
doi = {10.1016/s0167-4943(05)80065-2},
pmid = {18649860},
url = {https://doi.org/10.1016/s0167-4943(05)80065-2}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Prolonged treatments with MF and AS significantly decreased the psychogeriatric scores in scales and subscales, improved the cognitive performance (attention, concentration, memory, performance IQ, full IQ) and diminshed the deterioration index (ANOVA).
- Therapeutical effects of AS (a neurometabolic complex containing MF) were significantly superior against MF alone (ANCOVA).
- MF and AS actions are discussed in connection with the brain cholinergic system, lipid peroxidation and free radical scavengers, deceleration of the aging rate, brain and erythrocyte lipofuscinolysis, multiple anti-oxidant formula, multivitamin and multimineral supplementation and with the superiority of multitherapy versus monotherapy in senile dementia and for improving the IQ and the maladaptative behavior.
Why it matters
In 63 older people with mild-to-moderate Alzheimer-type dementia, both meclofenoxate and Antagonic-Stress improved psychogeriatric and cognitive scores over three months, with Antagonic-Stress performing better. This is an old, small trial and does not show a cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthHigh
How this study scored 29/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Archives of gerontology and geriatrics) |
| Journal's citation record | 1 / 4 | Archives of Gerontology and Geriatrics: journal h-index 132 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 1994 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 11 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 34 year(s) since 1994 |
| Impact for its field and year | 1 / 6 | Cited 0.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 0 / 4 | Last-listed author R Mateescu: h-index 4 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Victor Babeș University of Medicine and Pharmacy Timișoara: institution h-index 177 (OpenAlex) |
| Multi-centre collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18649860) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 29 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.